Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Vincent Rampersaud

Interventional Pain Medicine Flint, MI Medical Doctor

NPI 1144348152 CMS profile 142976

4800 S Saginaw St, Suite 1800, Flint, MI 48507

Open in the dashboard

General payments

$24,224

463 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$131,459 paid to institutions, not to them · program years 2024–2025

Through program year 2025, Vincent Rampersaud of Flint, MI is reported in the CMS Open Payments database as having received $24,224 across 463 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $131,459 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 88th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $13,417 104
2024 General $6,422 116
2023 General $1,479 53
2022 General $1,479 94
2021 General $349 15
2020 General $546 35
2019 General $532 46

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Vincent Rampersaud
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Vincent Rampersaud were reported at $13,417. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Vincent Rampersaud Interventional Pain Medicine median Middle half National median
2019 $532 $684 $216–$2,079 $163
2020 $546 $382 $122–$1,109 $114
2021 $349 $552 $167–$1,554 $132
2022 $1,479 $605 $187–$1,924 $149
2023 $1,479 $671 $195–$1,915 $160
2024 $6,422 $684 $206–$1,837 $164
2025 $13,417 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Nalu Medical, Inc. $11,385 37 payments
  2. Nevro Corp. $1,852 28 payments
  3. Boston Scientific Corporation $1,804 26 payments
  4. Medtronic, Inc. $1,676 24 payments
  5. Saluda Medical Americas, Inc. $1,525 4 payments
  6. AbbVie, Inc. $1,200 120 payments
  7. Globus Medical, Inc. $929 12 payments
  8. Horizon Therapeutics plc $780 92 payments
  9. Forte Bio-Pharma LLC $665 61 payments
  10. Abbott Laboratories $505 17 payments
  11. Other $1,902 42 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,092 445 payments
  2. Consulting Fee $8,100 6 payments
  3. Travel and Lodging $4,033 12 payments
Products named General payments · program years 2019–2025
  1. Nalu Neurostimulation System $11,385 37 payments
  2. Evoke $1,525 4 payments
  3. SYNCHROMEDII $1,469 20 payments
  4. Senza $970 12 payments
  5. General - Pain Management $944 9 payments
  6. UBRELVY $713 52 payments
  7. QULIPTA $709 100 payments
  8. PROLATE Pain $665 61 payments
  9. PROLATE Pain $665 61 payments
  10. PROLATE Pain $665 61 payments
  11. Other $6,897 332 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

1,350

Median for Interventional Pain Management: 1,220

Drug cost

$64,116

Median for Interventional Pain Management: $39,344

Branded share of claims

33.2%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 98 $16,304
Buprenorphine Generic 84 $14,500
Belbuca Buprenorphine Hcl Brand 15 $11,028
Movantik Naloxegol Oxalate Brand 11 $4,327
Diclofenac Sodium Generic 127 $3,929
Methocarbamol Generic 26 $3,398
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 207 $2,642
Gabapentin Generic 217 $2,224
Acetaminophen-Codeine Acetaminophen With Codeine Brand 60 $952
Pregabalin Generic 69 $864

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 46 billing codes

Paid by Medicare

$82,388

Medicare's payments for the services billed

Medicare patients

255

Average age 64

Services billed

1,558

165 women, 90 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 37%
Diabetes 35%
COPD 29%
Ischemic heart disease 22%
Chronic kidney disease 22%
Heart failure 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
PROLATE
$313 — —
UBRELVY
$195 — —
NALOCET
$78 — —
QULIPTA
$67 — —
Qutenza
$66 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

463 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record